Doseology Sciences (MOOD) AI Stock Analysis

• Market Cap: C$4.81M
• Dividend Yield: N/A
• Average Volume (3M): 1.79K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.84
• Revenue Growth: -50.89%
• EPS Growth: -32.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 8,011,621
• 10 Day Avg. Volume: 3,383
• 30 Day Avg. Volume: 1,793
• PEG Ratio: -0.49
• Price to Book (P/B): 3.46
• Price to Sales (P/S): 113.73
• P/FCF Ratio: -14.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.52 ▼(-1.51% Downside)

The score is mainly constrained by weak financial performance—small/volatile revenue, continued losses, and negative operating/free cash flow—despite a clean, low-debt balance sheet. Technicals are moderately supportive with price above major moving averages but neutral momentum, while valuation is hindered by negative earnings and no dividend yield data.

Positive Factors

Balance sheet strength

Effectively zero debt and an equity cushion reduce refinancing and leverage risk, giving the company durable financial flexibility. This balance sheet strength supports funding product development or strategic initiatives without immediate insolvency pressure, improving resilience.

Focused consumer product strategy

A clear focus on dosage-controlled cannabinoid consumer and wellness products targets a structural growth market. Owning differentiated formulations and consumer brands underpins repeatable revenue potential and customer loyalty if distribution and regulatory access scale over the medium term.

Positive gross profit

Positive gross margin indicates viable unit economics at the product level, suggesting the business can cover direct costs as sales scale. If operating expenses are contained and revenue growth resumes, gross-profitability provides a foundation for future margin expansion.

Negative Factors

Small, volatile and declining revenue

Very small and declining revenue undermines scalability and predictability of cash flows. Persistent top-line weakness limits the company's ability to absorb fixed costs or invest in marketing and distribution, making long-term growth and margin improvement difficult without structural revenue recovery.

Consistently negative operating and free cash flow

Ongoing negative operating and free cash flow means the business cannot self-fund operations or growth. Continued cash burn forces reliance on external financing, increasing dilution and execution risk, and limiting the firm's ability to make durable, non-reversible investments.

Sustained losses eroding shareholder returns

Sustained net losses and negative ROE indicate operations fail to generate shareholder value, progressively reducing equity quality. Over months this can constrain strategic options, deter partnerships, and raise the probability of dilution or restructuring if profitability is not restored.

Doseology Sciences Business Overview & Revenue Model

Company Description

Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.

How the Company Makes Money

Doseology Sciences, Inc. generates revenue through the sale of its health and wellness products. The company's primary revenue streams come from direct-to-consumer sales via their online platform and distribution through retail partnerships. These partnerships may include health food stores, pharmacies, and other retailers that carry wellness products. Additionally, the company may engage in licensing agreements or partnerships that allow them to expand their product reach and customer base. Marketing and strategic collaborations help to bolster their market presence and drive sales growth.

Doseology Sciences Financial Statement Overview

Summary

Doseology Sciences, Inc. faces substantial financial challenges typical of early-stage biotechnology firms. While revenue growth is a positive sign, the sustained losses and negative cash flows highlight the need for strategic changes to achieve profitability. The strong cash position provides some buffer, but the company must address its operational inefficiencies to ensure long-term viability.

Income Statement

The company shows a significant improvement in revenue over the past periods, though it remains small in absolute terms. However, profitability metrics are weak with negative gross, EBIT, and net profit margins, indicating persistent loss-making operations. The negative trajectory in EBIT and EBITDA margins highlights ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position, with no current debt and a substantial amount of cash relative to liabilities. However, the declining total assets and stockholders' equity over recent periods suggest potential liquidity and solvency concerns if the trend continues without revenue growth.

Cash Flow

Cash flow from operations remains negative, reflecting ongoing cash burn. Free cash flow is also negative, although the company has managed to maintain a stable cash position. The lack of positive cash flow generation is a concern for long-term sustainability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	20.29K	42.56K	98.52K	43.09K	16.05K	0.00
Gross Profit	9.98K	18.89K	72.09K	41.29K	-148.38K	-92.83K
EBITDA	-389.53K	-471.61K	-319.48K	-1.78M	-1.72M	-1.47M
Net Income	-370.38K	-447.79K	-339.85K	-1.78M	-1.94M	-1.63M
Balance Sheet
Total Assets	1.49M	1.49M	1.10M	1.40M	3.87M	5.99M
Cash, Cash Equivalents and Short-Term Investments	1.43M	1.43M	1.06M	1.30M	1.87M	3.73M
Total Debt	0.00	0.00	0.00	50.27K	746.10K	687.54K
Total Liabilities	94.11K	94.11K	82.49K	99.19K	871.51K	3.41M
Stockholders Equity	1.40M	1.40M	1.02M	1.30M	3.00M	2.58M
Cash Flow
Free Cash Flow	-230.84K	-342.24K	-235.12K	-481.05K	-1.72M	-2.54M
Operating Cash Flow	-230.85K	-342.24K	-235.12K	-481.05K	-1.71M	-2.37M
Investing Cash Flow	0.00	0.00	0.00	0.00	-7.88K	-26.05K
Financing Cash Flow	711.68K	711.68K	-6.14K	-91.88K	-140.08K	5.79M

Doseology Sciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Neutral. The current price of 0.53 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 0.59, and below the 200-day MA of 0.60, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.99 is Neutral, neither overbought nor oversold. The STOCH value of 63.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MOOD.

Doseology Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYBN	48 Neutral	C$1.92M	-0.02	-53.20%	―	―	33.28%
MOOD	47 Neutral	C$4.81M	-5.96	-41.36%	―	-50.89%	-32.33%
ENBI	47 Neutral	C$1.39M	-3.36	-107.76%	―	―	34.22%
LEXT	42 Neutral	C$1.48M	-0.42	-293.33%	―	―	28.37%

Doseology Sciences Corporate Events

Doseology Launches Investor Communications Initiative to Boost Market Engagement

Doseology Sciences Inc. has launched an Investor Communications Initiative to enhance its disclosure practices and investor engagement, supporting its long-term commercial and capital-markets strategy. This initiative includes partnerships with Guerilla Capital and Maynard Communications Ltd. to improve corporate updates distribution, visibility, and media exposure. The program aims to align Doseology’s operations with enhanced reporting standards and capitalize on the growing demand for oral stimulant products, positioning the company advantageously within the evolving market.

Doseology Secures Strategic Manufacturing Agreement for Market Readiness

Doseology Sciences Inc. has announced a significant milestone with its subsidiary, Doseology USA Inc., securing a strategic manufacturing agreement with a leading North American partner. This agreement marks a crucial step in Doseology’s transition from research and development to commercial deployment of its oral stimulant pouches. The partnership ensures the company has the necessary manufacturing capacity, regulatory compliance, and operational infrastructure to enter the market effectively. This development is expected to enhance Doseology’s market positioning and shareholder value by establishing a solid foundation for scalable and responsible commercialization.